Cannabis stocks are having a rough go right now, with even some of the most profitable pot stocks taking a hit. So it’s probably not a surprise to learn that shares of one of the most promising clinical-stage cannabis companies, Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), have been taking an outsized hit.
Despite the shellacking, the outlook for Zynerba Pharmaceuticals stock is exceptional.
Why Investors Should Watch Zynerba Pharmaceuticals Inc
The post Zynerba Pharmaceuticals Stock: This Pot Stock Has 715%+ Upside appeared first on Profit Confidential.